

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50164/026004
	Serial No.	10/670,488
	Applicant	Jost-Price et al.
	Filing Date	September 24, 2003
	Group	1617
	IDS Filed	June 9, 2008

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	5,368,861	Nov. 29, 1994	Ushimaru et al.
	2002/0012966	Jan. 31, 2002	Shi et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Bymaster et al., "Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters <i>In Vitro</i> and <i>In Vivo</i> , Human Serotonin Receptor Subtypes, and Other Neuronal Receptors," <i>Europharmacology</i> 25:871-880, 2001.
	Elenkov, "Stress Hormones, Proinflammatory and Antiinflammatory Cytokines, and Autoimmunity," <i>Ann. N.Y. Acad. Sci.</i> 966:290-303, 2002.
	Marchovsky, "Interactions Between Medicaments" <i>Novaya Volna</i> 1:11, 2001.
	Marchovsky, "Interactions Between Medicaments" <i>Novaya Volna</i> 1:11, 2001. (English translation)
	Marchovsky, "Adrenal Cortical Hormones and Synthetic Analogues Thereof," <i>Novaya Volna</i> 2:25, 2001.
	Marchovsky, "Adrenal Cortical Hormones and Synthetic Analogues Thereof," <i>Novaya Volna</i> 2:25, 2001. (English translation)
	Song and Leonard, "Serotonin Reuptake Inhibitors Reverse the Impairments in Behavior, Neurotransmitter and Immune Functions in the Olfactory Bulbectomized Rat," <i>Human Psychopharmacol.</i> 9:135-146, 1994.
	PDR [®] Electronic Library TM for Paxil [®] (paroxetine hydrochloride).

EXAMINER	/Sahar Javanmard/	DATE CONSIDERED	08/27/2008
----------	-------------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./
 EXAMINER: I have read the entire communication and have considered the references cited therein. I have lined through the references I have considered in the communication with the next communication to applicant.